Top

Published in:

01-09-2021 | Chronic Myeloid Leukemia | Case Report

Bosutinib-induced osteonecrosis of the jaw in a patient with chronic myeloid leukemia: a case report

Authors: Yoshinari Myoken, Yoshinori Fujita, Ryota Imanaka, Shigeaki Toratani

Published in: Oral and Maxillofacial Surgery | Issue 3/2021

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is an uncommon adverse drug reaction that can be induced by certain therapeutic drugs, including antiresorptive and antiangiogenic agents. Here, we describe the first case of ONJ induced by bosutinib, a tyrosine kinase inhibitor, in a patient with chronic myeloid leukemia (CML) who was not taking an antiresorptive agent. A 65-year-old male with no history of either antiresorptive treatment or dental surgery but diagnosed with CML had been undergoing treatment with bosutinib for 2 years. He developed right mandibular stage 2 osteonecrosis. The patient eventually underwent extensive surgery consisting of removal of the necrotic bone and infected soft tissue in combination with nasolabial flap reconstruction. He obtained complete resolution of MRONJ at 12 months postoperatively. As new cancer therapies become available, it is important that clinicians are aware of this novel case of bosutinib-induced ONJ in a patient undergoing CML treatment.

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 72:1938–1956CrossRef

Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein JB, Elad S, Campisi G, Tsoukalas N, Bektas-Kayhan K, MASCC Bone Study Group et al (2019) Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer 27:383–394CrossRef

Abel Mahedi Mohamed H, Nielsen CEN, Schiodt M (2018) Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol 125:157–163CrossRef

Won AM, Boddu P, Otun AO, Aponte-Wesson R, Chambers M (2018) Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol 126:e208–e211CrossRef

Vivano M, Rossi M, Cocca S (2017) A rare case of osteonecrosis of the jaw related to imatinib. J Korean Assoc Oral Maxillofac Surg 43:120–124CrossRef

Mauceri R, Panzarella V, Morreale I, Campisi G (2019) Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib. Int J Oral Maxillofac Surg 48:1530–1532CrossRef

Akkach S, Shukla L, Morgan D (2019) Everolimus-induced osteonecrosis of the jaw in the absence of bisphosphonates: a case report. Br J Oral Maxillofac Surg 57:688–690CrossRef

Cortes JE, Apperley JF, DeAngelo DJ, Deininger MW, Kota VK, Rousselot P, Gambacorti-Passerini C (2018) Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol 11:143CrossRef

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH (2018) Bosutinib versus Imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol 36:231–237CrossRef

10.

Lemound J, Muecke T, Zeller AN, Lichtenstein J, Eckardt A, Gellrich NC (2018) Nasolabial flap improves healing in medication-related osteonecrosis of the jaw. J Oral Maxillofac Surg 76:877–885CrossRef

11.

Bieerkehazhi S, Chen Z, Zhao Y, Yu Y, Zhang H, Vasudevan SA, Woodfield SE, Tao L, Yi JS, Muscal JA, Pang JC, Guan S, Zhang H, Nuchtern JG, Li H, Li H, Yang J (2017) Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling. Oncotarget 8:1469–1480CrossRef

12.

Gover-Proaktor A, Granot G, Pasmanik-Chor M, Pasvolsky O, Shapira S, Raz O, Raanani P, Leader A (2019) Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells. Leuk Lymphoma 60:189–199CrossRef

13.

Hayashida S, Soutome S, Yanamoto S, Fujita S, Hasegawa T, Komori T, Kojima Y, Miyamoto H, Shibuya Y, Ueda N, Kirita T, Nakahara H, Shinohara M, Umeda M (2017) Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: a multicenter retrospective study with propensity score matching analysis. J Bone Miner Res 32:2022–2029CrossRef

14.

Mücke T, Koerdt S, Jung M, Mitchell DA, Wolff KD, Kesting MR, Loeffelbein DJ (2016) The role of mylohyoid flap in the treatment of bisphosphonate-related osteonecrosis of the jaws. J Craniomaxillofac Surg 44:369–373CrossRef

15.

Myoken Y, Fujita Y, Okamoto T (2020) Modified submental island flap for the surgical treatment of 4 patients with stage 3 medication-related osteonecrosis of the mandible. J Oral Maxillofac Surg 78:29–34CrossRef

16.

Myoken Y, Fujita Y, Kawamoto K, Toratani S (2020) Osteonecrosis of the jaw in a metastatic lung cancer patient with bone metastases undergoing pembrolizumab+denosumab combination therapy: case report and literature review. Oral Oncol 27:104874. https://doi.org/10.1016/j.oraloncology.2020.104874CrossRef

17.

Ristow O, Rückschloß T, Moratin J, Müller M, Kühle R, Dominik H, Pilz M, Shavlokhova V, Otto S, Hoffmann J et al (2020) Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-a randomized pilot trial. Oral Dis 2020:17. https://doi.org/10.1111/odi.13556CrossRef

Title: Bosutinib-induced osteonecrosis of the jaw in a patient with chronic myeloid leukemia: a case report
Authors: Yoshinari Myoken
Yoshinori Fujita
Ryota Imanaka
Shigeaki Toratani
Publication date: 01-09-2021
Publisher: Springer Berlin Heidelberg
Keywords: Chronic Myeloid Leukemia
Tyrosine Kinase Inhibitors
Osteonecrosis
Tyrosine Kinase Inhibitors
Bosutinib
Dasatinib
Imatinib
Published in: Oral and Maxillofacial Surgery / Issue 3/2021
Print ISSN: 1865-1550
Electronic ISSN: 1865-1569
DOI: https://doi.org/10.1007/s10006-020-00931-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Bosutinib-induced osteonecrosis of the jaw in a patient with chronic myeloid leukemia: a case report

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2021

Infant mandibular distraction in absence of ascending ramus: case series

Evaluation of canalis sinuosus in individuals with cleft lip and palate: a cross-sectional study using cone beam computed tomography

Survival after parotid gland metastases of cutaneous squamous cell carcinoma of the head and neck

Rugby-related adult maxillofacial trauma injuries: a NEISS database study

The use of steroids in cervicofacial infections in UK OMFS departments: a Maxillofacial Surgery Trainees Research Collaborative (MTReC) study

Health-related quality of life in patients surgically treated for orbital blow-out fracture: a prospective study